Back to results
US 2025/0145652 A1Published application
Inorganic salts of nicotinamide mononucleotide as anti-aging agents
OwnerSebastian Mario MARCUCCIO, Rohan David JOYCE +3inventors
InventorsSebastian Mario MARCUCCIO, Rohan David JOYCE, Michel WATHIER, Roland DOLLE, Simon TUCKER
Life of this patent
Estimating the term…
Abstract
The present invention relates to inorganic salts of nicotinamide mononucleotides and compositions of Formula I, useful in the treatment of disorders and diseases associated with deficiencies in NAD+: wherein A, M1, k, R1 and R2 are as described herein.
Claims24
A salt of Formula (I):
- or enantiomer, stereoisomer, or tautomer thereof,
- wherein
- A is NRaRb;
- M1 is an inorganic cation;
- R1 and R2 are independently H, C1-C6alkyl, C1-C6haloalkyl, (C0-C3alkylene)C(O)C1-C6alkyl, —C(O)ORa, —C(O)NRaRb, or —[CH2—CH2—O]n—Ra,
- or R1 and R2, together with the atom to which they are attached, form a 5-membered heterocyclic ring optionally substituted with one or more substituents selected from C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, (C0-C3alkylene)C3-C8cycloakyl, (C0-C3alkylene)heterocycloakyl, (C0-C3alkylene)C6-C14aryl, and (C0-C3alkylene)heteroaryl;
- Ra and Rb are independently, at each occurrence, H, or C1-C6alkyl, wherein the alkyl is optionally substituted with one or more substituents selected from (C0-C3alkylene)C3-C8cycloakyl, (C0-C3alkylene)heterocycloakyl, (C0-C3alkylene)C6-C14aryl, and (C0-C3alkylene)heteroaryl;
- k is 1 or 2;
- and
- n is an integer from 1 to 8,
- provided M1 is not Na.
8 more elements
(canceled)
(canceled)
A method of treating or preventing infertility comprising administering to a subject in need thereof, an effective amount of a salt of Formula I:
- or enantiomer, stereoisomer, or tautomer thereof,
- wherein
- A is NRaRb;
- M1 is an inorganic cation;
- R1 and R2 are independently H, C1-C6alkyl, C1-C6haloalkyl, (C0-C3alkylene)C(O)C1-C6alkyl, —C(O)ORa, —C(O)NRaRb, or —[CH2—CH2—O]n—Ra,
- or R1 and R2, together with the atom to which they are attached, form a 5-membered heterocyclic ring optionally substituted with one or more substituents selected from C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, (C0-C3alkylene)C3-C8cycloakyl, (C0-C3alkylene)heterocycloakyl, (C0-C3alkylene)C6-C14aryl, and (C0-C3alkylene)heteroaryl;
- Ra and Rb are independently, at each occurrence, H, or C1-C6alkyl, wherein the alkyl is optionally substituted with one or more substituents selected from (C0-C3alkylene)C3-C8cycloakyl, (C0-C3alkylene)heterocycloakyl, (C0-C3alkylene)C6-C14aryl, and (C0-C3alkylene)heteroaryl;
- k is 1 or 2;
- and
- n is an integer from 1 to 8.
7 more elements
(canceled)
(canceled)
17-19. (canceled)
24-35. (canceled)
-38. (canceled)
Dependencies are inferred from the claim text.